Takeda winds down Theravance pact, culls partnered Crohn's program after PhII flops
Takeda revealed in its latest quarter filing that it’s ending a seven-year alliance with Theravance as the companies fold a program that flopped in Phase IIb, while also giving the axe to a second partnership with France’s Enterome in Crohn’s. These programs were among seven trials Takeda is cutting for various cancers and other diseases amidst a plan to lay off more than 180 workers.
TAK-954, a candidate being developed in Phase II trials for patients before surgery to see if it could enhance the recovery of gastrointestinal function after surgery to resection the small or large intestine, was also cut. Some patients also got the drug post-surgery to see if it helped at all in the trial. Takeda noted in its quarterly report that the Phase IIb study for TAK-954 did not meet its endpoints.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.